Our response to COVID-19
Johnson & Johnson, as the world’s largest and most broadly-based healthcare company, has mobilised its resources, including expediting the development and production of a vaccine, in response to COVID-19. Information on our response is available at https://www.jnj.com/coronavirus.
Medicine supply in New Zealand
Janssen continues to supply its medicines in New Zealand and there are no disruptions due to COVID-19.
Employees visiting healthcare facilities and interactions with healthcare professionals
We are prioritising the interests of our patients and healthcare professionals at this time and we will do what we can to minimise the spread of infection, and the impact on those most vulnerable. Recognising that a significant proportion of the patients we serve are immuno-compromised, we are suspending visits to hospitals and clinics until at least until the end of April 2020. We will continue to follow the advice of the New Zealand Government.
Operation of the Janssen New Zealand business
To make sure that Janssen New Zealand can continue to serve our patients, healthcare professionals and the community, we have changed some aspects of the way we operate. In addition to suspending visits to hospitals and clinics, we have also undertaken the following measures:
All employees who can meet their job responsibilities by working from home.
We will support meetings with healthcare professionals and facilities through virtual platforms rather than in person. Any planned conferences will be deferred or take place supported by virtual platforms.
As a leader in global health, our top priority remains our patients, customers and employees.
We remain available via our normal channels: https://www.janssen.com/newzealand/contact-us
Government information and resources on COVID-19
Dedicated Healthline for COVID-19: 0800 358 5453 (or for international SIMs +64 9 358 5453).
As a global leader in health, our top priority remains our patients, customers and employees.